Medicament combination for regrouping leech essence

Abstract

The invention provides a medicine composition for curing heparin-induced thrombocytopenia. The main components include Lepirudin and salt which can be accepted by the medicine. The medicine composition has value of curing the heparin-induced thrombocytopenia. The Lepirudin in the invention mainly has the following two advantages: (1) light molecular weight and nearly no antigenicity; (2)nearly no toxicity.

Description

technical field [0001] The invention relates to a pharmaceutical combination of recombinant hirudin, which has the effect of treating heparin-related thrombocytopenia. Background technique [0002] Recombinant hirudin is a specific thrombin inhibitor. It is an aglycosylated single-chain polypeptide containing 65 or 66 amino acid residues, with a molecular weight of about 7kD. For disulfide bonds, it stabilizes its spatial conformation; its C-terminus contains more acidic amino acids. [0003] Heparin-associated thrombocytopenia (HAT) is the most serious adverse reaction during heparin therapy. There are 2 types of HAT with very different etiologies. HAT I is that heparin directly activates platelets through non-immune ways, causing platelet aggregation and reduction. In 10% of patients receiving heparin treatment, the platelet count decreased to 100×109 / L on the first 1 to 2 days after administration. But it usually resolves on its own without treatment. HAT II is caused...

AI Technical Summary

Problems solved by technology

In vitro tests have shown that low molecular weight heparin and unfractionated heparin have 78%-88% cross-reactivity to anti-platelet factor 4 and anti-heparin antibodies. Improper use may aggravate HAT II and cause fatal complications